Literature DB >> 19451417

Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.

Rita S Mehta, Donna Jackson, Toni Schubbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451417     DOI： 10.1200/JCO.2009.22.9377

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.

Authors:  Pedro M Enriquez-Navas; Yoonseok Kam; Tuhin Das; Sabrina Hassan; Ariosto Silva; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Sci Transl Med       Date:  2016-02-24       Impact factor: 17.956

2.  Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.

Authors:  Leona Bessonova; Thomas H Taylor; Rita S Mehta; Jason A Zell; Hoda Anton-Culver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-07       Impact factor: 4.254

3.  Continued Exploration of Bevacizumab in Breast Cancer.

Authors:  Rita S Mehta; Min-Ying Su
Journal:  Ann Surg Oncol       Date:  2010-02       Impact factor: 5.344
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.